All In Biotech

Drug Trial Radar · NCT05552755

Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)

A Phase 1b-2, Multicenter, Trial to Evaluate the Efficacy, Safety, Pharmacokintetics, and Pharmacodynamics of REC-4881 in Patients With Familial Adenomatous Polyposis (FAP)

Last checked: Nov 19, 2026Latest source record: Jun 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

67

Planned (sponsor's estimate)

Start

Jul 10, 2023

Primary completion

Jun 2027

Study completion Sep 2027

Sponsor

Lead sponsor
Recursion Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Sep 23, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, two-part trial in participants with FAP.

Conditions

  • Familial Adenomatous Polyposis

Interventions

  • REC-4881Drug

    REC-4881 capsules

  • PlaceboDrug

    Placebo capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Maximum (Peak) Plasma Drug Concentration (Cmax) of REC-4881Time frame: Day 1 through Day 43
  2. Part 1: Time to Reach Cmax (Tmax) of REC-4881Time frame: Day 1 through Day 43
  3. Part 1: Area Under the Plasma Concentration-time Curve (AUC) of REC-4881Time frame: Day 1 through Day 43
  4. Part 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: Day 1 through up to Week 37
  5. Part 2: Number of Participants With Dose-limiting Toxicities (DLTs)Time frame: First 28 days of treatment
  6. Part 2: Number of Participants Who Discontinued TreatmentTime frame: Day 1 through up to Week 37
  7. Part 2: Number of Participants With Dose Modification Due to ToxicityTime frame: Day 1 through up to Week 37
  8. Part 2: Percent Change From Baseline in Polyp BurdenTime frame: Baseline, up to Week 37

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic - Scottsdale

    Scottsdale, Arizona · Active not recruiting

  • Del Sol Research Management

    Tucson, Arizona · Withdrawn

  • Medical Associates Research Group

    San Diego, California · Withdrawn

  • GI Pros

    Naples, Florida · Withdrawn

  • Digestive and Liver Center of Florida

    Orlando, Florida · Terminated

  • Gastroenterology Health Partners, PLLC

    New Albany, Indiana · Withdrawn

  • Tandem Clinical Research

    Marrero, Louisiana · Terminated

  • Corewell Health (Spectrum Health Hospitals Colorectal Cancer Multis)

    Grand Rapids, Michigan · Active not recruiting

  • Mayo Clinic - Rochester

    Rochester, Minnesota · Active not recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • Gastro One-8110 Walnut Rs

    Cordova, Tennessee · Terminated

  • Vanderbilt Digestive Center

    Nashville, Tennessee · Recruiting

  • Genetic Cancer Prevention Clinic - UT Southwestern

    Dallas, Texas · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Huntsman Cancer Institute and University of Utah

    Salt Lake City, Utah · Recruiting

  • Benaroya Research Institute at Virginia Mason

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.